883results about How to "Reduced bioavailability" patented technology

The invention relates to the technical field of soil heavy metal remediation, and specifically discloses a method for preparing an iron-based bio-char material, a prepared iron-based bio-char material, and a method for applying the iron-based bio-char material in treating soil heavy metal pollution. According to the material, biomass is adopted as a raw material; a high-temperature carbonization method is adopted; during the bio-char preparation process, an iron-containing compound is added, such that iron is doped according to a certain ratio, and the iron-based bio-char material with special structure and function is formed. The material has the advantages of simple preparation process, low production cost, and short production period. The obtained iron-based bio-char material has a unique effect in repairing arsenic-cadmium composite polluted soil. With the material, bio-availability of arsenic and cadmium in soil can be effectively reduced, arsenic and cadmium contents in agricultural products planted in the arsenic-cadmium composite polluted soil can be greatly reduced, and no toxic or side effect is caused on crops. The material is safe to apply, and can be used in a large scale in treatment of arsenic-cadmium composite polluted soil.

Drug storage and dispensing devices for dispensing a drug dosage form are disclosed. Devices having a housing defining a nonlinear passageway and a flexible push rod to move within the nonlinear passageway are disclosed. Devices having a flexible push rod coupled to a rotation actuating member at at an end portion thereof are also disclosed.

This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug.Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.